Effects of Cognitive Training on Chemotherapy-Induced Cognitive Impairment in Colon Cancer Patients Undergoing Treatment(Chemobrain) in Oncology Patients With Colon Cancer Undergoing Active Treatment
Launched by UNIVERSITY OF SALAMANCA · Nov 26, 2024
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, known as the Chemobrain study, is exploring how a cognitive training program can help colon cancer patients who are experiencing cognitive difficulties due to their treatment. Many people with cancer report problems with thinking and memory, often referred to as cancer-related cognitive impairment (CRCI). The goal of this study is to see if participating in a structured cognitive training program can improve these cognitive issues for patients currently undergoing treatment for colon cancer.
To be eligible for this study, participants must be adults aged 18 or older with a recent diagnosis of colon cancer and starting treatment. They should be capable of performing daily tasks and willing to participate in the study. Participants will be divided into two groups: one group will receive cognitive training along with an informational leaflet, and the other group will only receive the leaflet. The study will measure various aspects of cognitive function before and after the intervention to see if the training makes a difference. This research could lead to better support and resources for colon cancer patients facing cognitive challenges, helping them maintain their quality of life during treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being an adult (18 years or older). Having a recent pathological diagnosis of newly diagnosed colon cancer and starting oncological treatment.
- • Being fully capable of performing daily functions. Willingness to voluntarily participate in the study and signing the informed consent.
- Exclusion Criteria:
- • Lack of literacy skills or significant language comprehension deficits. Having a diagnosis of a Central Nervous System tumor or participating in another cognitive stimulation program.
- • Having a clinical diagnosis of a neurocognitive disorder as defined in the DSM-V.
- Withdrawal Criteria:
- • Dropping out of the program or not completing the final evaluation.
About University Of Salamanca
The University of Salamanca, one of the oldest and most prestigious universities in Spain, is a leading institution in academic research and clinical trials. With a strong commitment to advancing healthcare and medical science, the university engages in innovative research initiatives that address critical health challenges. Its clinical trial programs are characterized by rigorous scientific methodology, interdisciplinary collaboration, and a focus on ethical standards, ensuring high-quality outcomes that contribute to the advancement of medical knowledge and patient care. The University of Salamanca fosters partnerships with healthcare professionals and industry leaders, positioning itself at the forefront of clinical research and education.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported